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Sir,
We have read the recent interesting minireviews by Lo
and Hung (2007) and Uramoto and Mitsudomi (2007) regarding
epidermal growth factor receptor (EGFR) signalling and we
would like to add the following comment to strengthen some
issues of this important theme. Ligand-dependent activation of the
EGFR induces several signal-transduction pathways as well as
trafficking events that relocalise the receptors from the cell surface
to intracellular endocytic compartments that provide signal
specification. Accordingly, trafficking-dependent alterations
in receptor compartmentalisation are crucial regulatory mechan-
isms for EGFR signalling (Frey et al, 2006; Tanos and Pendergast,
2006). In the first step, activated receptors are removed from
cell membrane and are internalised into endosomes. In the second
step, EGFR may recycle back to the membrane for continued
signalling or is targeted for degradation (Orth and McNiven,
2007). The later step is generally appreciated as a signalling-
blocking process, although there are data suggesting that
internalised receptors might still interact with effector/adaptor
proteins and thus activate downstream cascades (Citri and Yarden,
2006). Defective internalisation of ligand-activated EGFR leads to
prolonged signalling and has been implicated in malignant
transformation (Marmor and Yarden, 2004). This might be partly
also related with the ‘short-lived’ observed clinical effect in some
cancer patients with the currently used EGFR-TKIs, as it has been
suggested that EGFR-TKIs (contrary to monoclonal antibodies)
cannot produce long-term EGFR suppression through receptor
internalisation and degradation. Moreover, EGFR endocytosis
might have important implications in the already tested as
well as the future co-administration of chemotherapy and EGFR-
TKIs, since it has been recently suggested that the in vitro
application of EGFR-TKIs before chemotherapeutic agents re-
presses EGFR degradation (Feng et al, 2006). Posttranslational
modifications are also a prerequisite of EGFR endocytosis.
Ras superfamily of GTPases regulate important biologic processes,
such as intracellular trafficking. RAB5 has been found to mediate
EGFR entry into the early endosome (Barbieri et al,
2004; Konstantinopoulos and Papavassiliou, 2007) and RAB11
facilitates EGFR recycling to the plasma membrane (Cullis
et al, 2002). Conversely, RAB7 is required for the degradation of
the ligand-activated EGFR by the lysosome (Ceresa and Bahr,
2006). Thus, modulation of RAB-GTPases could provide an
exciting alternative way of EGFR inhibition (Konstantinopoulos
et al, 2007, in press).
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